MedTrace Logo

EBOVAC-Salone Extension

NCT03820739 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 653

Last updated 2023-02-08

No results posted yet for this study

Summary

The VAC52150EBL3005 (EBOVAC-Salone Extension) is a cohort study evaluating the long-term safety and immunogenicity of the candidate Ebola vaccines Ad26.ZEBOV and MVA-BN®-Filo in participants who were exposed to these vaccines in the VAC52150EBL3001 trial (EBOVAC-Salone, ClinicalTrials.gov Identifier: NCT02509494). No investigational vaccine will be administered during this study. The study will consist of an enrolment visit, a number of study visits and an end-of-study visit.

Conditions

  • Ebola Virus Disease

Interventions

OTHER

Follow-up

No investigational vaccine will be administered during this study

OTHER

Blood sample collection

Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).

Sponsors & Collaborators

  • University of Sierra Leone

    collaborator OTHER

  • Janssen Vaccines & Prevention B.V.

    collaborator INDUSTRY

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Universiteit Antwerpen

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Deborah Watson-Jones, PhD · London School of Hygiene and Tropical Medicine

  • Bailah Leigh, MD · University of Sierra Leone

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-22
Primary Completion
2022-06-28
Completion
2022-07-14

Countries

  • Sierra Leone

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03820739 on ClinicalTrials.gov